We are live on ! Find out more
PIM

Partner Investment Management Portfolio holdings

AUM $13.9M
1-Year Est. Return 55.92%
This Fund
S&P 500
This Quarter Est. Return
+25.21%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$13.9M
AUM Growth
-$44.5M
Cap. Flow
-$44.7M
Cap. Flow %
-320.95%
Top 10 Hldgs %
48.07%
Holding
80
New
14
Increased
3
Reduced
23
Closed
39

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$510K
2
ELV icon
Elevance Health
ELV
+$459K
3
HUM icon
Humana
HUM
+$427K
4
CNC icon
Centene
CNC
+$371K
5
PFE icon
Pfizer
PFE
+$281K

Top Sells

Rank Stock Value
1
NXPI icon
NXP Semiconductors
NXPI
+$2.23M
2
MCHP icon
Microchip Technology
MCHP
+$2.23M
3
ZBH icon
Zimmer Biomet
ZBH
+$1.99M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.81M
5
TWLO icon
Twilio
TWLO
+$1.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Miscellaneous 0.9%
3 Communication Services 0%
4 Consumer Discretionary 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
1
DELISTED
Audentes Therapeutics, Inc
BOLD
$1.06M 7.65%
17,795
-7,575
-30% -$284K
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$911K 6.54%
8,421
-13,715
-62% -$1.47M
ALNA
3
DELISTED
Allena Pharmaceuticals
ALNA
$776K 5.57%
284,285
– –
GILD icon
4
Gilead Sciences
GILD
$181B
$708K 5.08%
10,898
-17,604
-62% -$1.15M
PEN icon
5
Penumbra
PEN
$12.7B
$608K 4.37%
3,699
-8,859
-71% -$1.41M
ZBH icon
6
Zimmer Biomet
ZBH
$19.2B
$552K 3.96%
3,800
-14,419
-79% -$1.99M
BIIB icon
7
Biogen
BIIB
$32.3B
$546K 3.92%
+1,839
New +$510K
NVRO
8
DELISTED
NEVRO CORP.
NVRO
$531K 3.81%
4,515
-1,252
-22% -$124K
ELV icon
9
Elevance Health
ELV
$85.5B
$504K 3.62%
+1,669
New +$459K
HUM icon
10
Humana
HUM
$46.3B
$494K 3.55%
+1,347
New +$427K
CI icon
11
Cigna
CI
$73.7B
$453K 3.25%
2,216
-4,916
-69% -$901K
IQV icon
12
IQVIA
IQV
$43.1B
$452K 3.25%
2,926
-5,641
-66% -$824K
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$12.5B
$451K 3.24%
5,329
-24,012
-82% -$1.81M
AERI
14
DELISTED
Aerie Pharmaceuticals
AERI
$436K 3.13%
18,035
+1,304
+8% +$27K
AGN
15
DELISTED
Allergan plc
AGN
$436K 3.13%
2,282
-5,092
-69% -$919K
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
$431K 3.09%
9,484
-19,393
-67% -$917K
CNC icon
17
Centene
CNC
$32B
$430K 3.09%
+6,838
New +$371K
NVS icon
18
Novartis
NVS
$292B
$392K 2.81%
4,270
-6,441
-60% -$578K
HCA icon
19
HCA Healthcare
HCA
$90.5B
$345K 2.48%
2,335
-5,165
-69% -$694K
PFE icon
20
Pfizer
PFE
$159B
$294K 2.11%
+7,897
New +$281K
ICUI icon
21
ICU Medical
ICUI
$4.38B
$258K 1.85%
+1,381
New +$238K
DERM
22
DELISTED
Dermira, Inc.
DERM
$256K 1.84%
16,892
-13,106
-44% -$113K
ICLR icon
23
Icon
ICLR
$13.1B
$241K 1.73%
1,402
-1,810
-56% -$279K
UNH icon
24
UnitedHealth
UNH
$353B
$233K 1.67%
+791
New +$207K
IRTC icon
25
iRhythm Holdings
IRTC
$3.96B
$231K 1.66%
3,389
-9,372
-73% -$636K
1
2 3 4

Similar funds

SWM
Sequoia Wealth Management Hoffman Estates, Illinois $12.9M AUM 25.75% 1-Year Est. Return
ACM
ADI Capital Management New York $17.5M AUM 49.32% 1-Year Est. Return
ECAU
Everett Capital Advisors (UK) London, United Kingdom $18.6M AUM 22.81% 1-Year Est. Return
SL
Signition LP New York $20M AUM 28.26% 1-Year Est. Return
DII
Domini Impact Investments New York $7.59M AUM 47.68% 1-Year Est. Return
FIM
FourPoints Investment Managers Paris, France $21.1M AUM 11.11% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
BHC
Balch Hill Capital San Francisco, California $22.8M AUM

Partner Investment Management's Q4 2019 Portfolio in Review

As of Q4 2019, Partner Investment Management held 80 positions worth $13.9M, down 76% from $58.4M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Partner Investment Management withdrew a net $44.7M in Q4 2019, closing 39 positions and reducing 23 holdings. Its most notable exit was NXP Semiconductors, an estimated $2.23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 53% a quarter earlier, followed by Miscellaneous and Communication Services.

Against the trend, Partner Investment Management opened a new position in Biogen worth $546K.

  • Partner Investment Management's largest Q4 2019 buy was Biogen: 1,839 shares worth $546K.
  • Partner Investment Management added most to Axonics, Inc. Common Stock in Q4 2019, an estimated $48.7K increase.
  • Partner Investment Management's biggest Q4 2019 reduction was Zimmer Biomet, cutting an estimated $1.99M.
  • Partner Investment Management fully exited NXP Semiconductors in Q4 2019, selling an estimated $2.23M.
  • Partner Investment Management's ten largest holdings make up 48% of its $13.9M portfolio in Q4 2019.
  • Partner Investment Management opened 14 new positions and closed 39 in Q4 2019.
  • Partner Investment Management's portfolio value fell 76% quarter-over-quarter to $13.9M.

Based on Partner Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.